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Abstract Up to 30% of curatively resected colorectal
cancer patients with tumor-negative lymph nodes, show
disease recurrence. We assessed whether these high-risk
patients can be identified by examining primary tumors for
the following blood and lymphatic vasculature markers: A)
sialyl Lewis X (sLeX), vascular endothelial growth factor
(VEGF)-C and VEGF-D expression; B) blood and lym-
phatic microvessel density (BMVD/LMVD); and C) the
presence of blood and lymphatic vessel invasion. Thirty-six
cases (disease recurrence within 5 years) and 72 controls
(no disease recurrence for at least 5 years) were selected in
a case-control design. Tumor sections were stained by
antibodies CSLEX1 (sLeX), anti-VEGF-C, anti-VEGF-D,
anti-CD31 (BMVD) or D2–40 (LMVD) to determine the
parameters as mentioned above. A multivariate analysis
showed sLeX expression and high LMVD (odds ratio 5.1,
95% confidence interval 1.3–20.0 and odds ratio 3.1, 95%
confidence interval 1.0–10.0, respectively) to be indepen-
dent factors predicting disease recurrence. Expression of
sLeX correlated with liver metastases (P=0.015). A high
LMVD was related to regional intra-abdominal or intra-
pelvic metastases in lymph nodes and distant metastases
other than in the liver and lungs such as peritoneum, bones,
brain and adrenal glands (P=0.004). A high BMVD in the
invasive front correlated with lung metastases (P=0.018).
We show that high-risk node-negative colorectal cancer
patients can be identified by primary tumor assessment for
sLeX expression and LMVD. Our results are consistent
with the notion that both lymphatic and hematogenous
metastasis play a role in colorectal cancer.
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Introduction
In most countries, patients with curatively resected
colorectal cancer (CRC) without nodal tumor involve-
ment do not receive adjuvant systemic therapy since
meaningful survival benefits have not been proven yet
[1, 2]. However, 10 to 30 percent of these patients show
disease recurrence [3, 4]. Although, a small survival
benefit has been reported in stage II CRC patients who
received 5-fluorouracil [5], adjuvant systemic treatment of
all node-negative CRC patients will lead to overtreatment
and unnecessary complications due to adverse effects
of the treatment. Providing only high-risk patients with
adjuvant systemic therapy prevents unnecessary treatment
and leads to an optimized cure rate. Lymph node-negative
CRC patients at risk for disease recurrence may be
identified by tumor features known to determine the pro-
cess of invasion and metastasis which was the focus of
this study.
Invasion and metastasis can be facilitated by proteins
which stimulate tumor cell attachment to host cellular or
extracellular matrix determinants, proteolysis of extracellular
matrix host barriers such as the basement membrane, tumor
cell migration and formation of distant metastases [6].
Tumor cells are expected to express similar molecules as
leucocytes to interact with blood and lymphatic microvessel
endothelium. Normally, the blood group-related antigen
sialyl Lewis X (sLeX) is located on the membrane of
neutrophils and binds to the endothelial leukocyte adhesion
molecule-1 also known as E-selectin which leads to
neutrophil extravasation and migration into tissue [7]. In
cancer, the interaction of sLeX on tumor cells and E-
selectin was shown to mediate adhesion of tumor cells to
endothelial cells [8]. Previous publications have reported
high sLeX expression on tumor cells to be a prognostic
factor in colorectal cancer [9, 10].
The vascular endothelial growth factor (VEGF) family
has been reported to be involved in the formation of blood
and lymphatic microvessels [11] through which tumor cells
disseminate. The VEGF family includes five ligands:
VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placenta
growth factor and three receptors: VEGFR-1, VEGFR-2,
and VEGFR-3 [12]. Studies have shown that VEGF-C and
VEGF-D, which are ligands for VEGFR-3, can induce
tumor lymphangiogenesis and lymphatic metastasis
[13, 14].
Also, the number and tumor invasion of blood and
lymphatic microvessels have been shown to play a role in
the process of metastasis [15–17].
In this study, we examined whether disease recurrence
in lymph node-negative CRC patients could be predicted
by assessing their primary tumors for: A) the expression
of angiogenic and lymphangiogenic factors, sLeX, VEGF-
C, and VEGF-D; B) blood and lymphatic microvessel
density; and C) the presence of blood and lymphatic vessel
invasion.
Materials and Methods
Patients
Between January 1981 and December 2001, 1044 patients
underwent surgery for a primary CRC at the LUMC. For
the present study, a selection was made from the total group
of patients with tumor-negative lymph nodes (N0) and
without metastases (M0) at the time of surgery (n=506).
Patients who were operated on their first CRC in another
hospital, or who were diagnosed with another invasive
malignancy before or within 5 years after the date of
diagnosis of the primary colorectal carcinoma, and patients
who developed a local recurrence were excluded for the
present study. Cases (n=36) were defined as patients who
suffered from regional or distant recurrent disease at least 3
months after but within 5 years after the date of diagnosis
of primary CRC. Cases developed liver metastases (n=23),
and/or lung metastases (n=8), and/or regional metastases
which were considered intra-abdominal or intrapelvic
metastases in lymph nodes or in connective tissue (n=7),
and/or peritoneal metastases (n=5), and/or other distant
metastases (n=8). The latter consists of brain, bone or
adrenal metastases. Controls were patients who did not
develop locoregional or distant disease within 5 years after
diagnosis of primary CRC. For each case two controls were
matched for TNM stage, date of incidence and date of birth,
leading to a total number of 72 controls. Of patients with
rectal carcinoma, two had received preoperative and three
had received postoperative radiotherapy. None of the
patients had received adjuvant chemotherapy.
A tumor was considered mucinous when more than 50%
of its volume consisted of mucinous component. Tumor
growth pattern at the invasive margin was classified as
either expanding also known as pushing or infiltrative
based on the predominant morphology as defined by Jass
et al. [18] Clinicopathologic characteristics of patients are
shown in Table 1.
142 F.S. Doekhie et al.Immunohistochemistry
Four μm sections were cut from formalin-fixed paraffin-
embedded tumors, transferred to aminopropylethoxysilane-
(APES) coated slides, and dried overnight at 37°C. One
section of each tumor was stained by hematoxylin and
eosin (HE). Five sections of each tumor were respectively
stained with CSLEX1 also known as CD15s (Becton
Dickinson Pharmingen, San Jose, California, 1:150), a
monoclonal antibody that binds to sLeX, polyclonal anti-
VEGF-C (Zymed, San Francisco, California, 1:100),
monoclonal anti-VEGF-D (Research and Development
Systems, Minneapolis, USA, 1:400), monoclonal antibody
anti-CD31 (Dako, Glostrup, Denmark, 1:300), or monoclonal
antibody D2–40 (Signet Laboratories, Dedham, MA, USA,
1:100). All primary antibodies were diluted in phosphate-
bufferedsaline(PBS)with1%bovineserumalbumine(BSA).
As negative control the sections were incubated with only
PBS/1% BSA. For the immunohistochemical staining proce-
dure, the sections were deparaffinized in xylene. Endogenous
Table 1 Patient and primary tumor characteristics
Characteristics All patients (n=108) Cases (n=36) Controls (n=72) P
h
Number Percent Number Percent Number Percent
Sex
Female 53 49 16 44 37 51 0.496
Male 55 51 20 56 35 49
Age (years)
a 67±12 67±12 67±12 0.911
i
TNM stage
b
I 6 6 2 6 4 6 1.000
j
II 102 94 34 94 68 94
T stage
c
T2 6 6 2 6 4 6 0.126
T3 88 82 26 72 62 86
T4 14 13 8 22 6 8
Tumor size (cm) (n=104)
a, d 5.1±2.0 4.9±1.9 (n=34) 5.2±2.1(n=70) 0.539
i
Tumor location
Colon (coecum–sigmoid) 89 82 30 83 59 82 0.858
Rectum (rectosigmoid−rectum) 19 18 6 17 13 18
Differentiation
Good 27 25 9 25 18 25 0.912
Moderate 68 63 22 61 46 64
Poor 13 12 5 14 8 11
Mucinous
No 98 91 32 89 66 92 0.728
j
Yes 10 9 4 11 6 8
Growth pattern (n=97)
e
Expanding or pushing 70 72 20 60 50 79 0.031
Infiltrating 27 28 14 41 13 21
Number of lymph nodes
f 6( 1 –26) 6 (1–18) 6 (1–26) 0.096
k
Preoperative serum CEA level (n=43)
g
<6 ug/l 30 70 5 56 25 74 0.417
j
≥6 ug/l 13 30 4 44 9 26
CEA Carcinoembryonic antigen
aPresented as mean±standard deviation
bAccording to the 6th edition of the TNM classification [39]
cIf T2 and T3 stage were combined, the P-value was 0.043; this comparison was therefore used in the logistic regression
dTumor size could not be found in pathology reports from four patients
ePatients were excluded from analysis if no invasive front was found in primary tumor sections
fPresented as median and range between brackets
gSerum CEA had been determined in only 43 of 108 patients as it was not a standard procedure
hChi-square test of cases versus controls, unless mentioned otherwise
iStudent T-test
jFisher’s exact test
kMann–Whitney test
Prognostic factors in colorectal cancer 143peroxidase was blocked in methanol containing 0.3% hydro-
gen peroxide at room temperature for 20 min. Subsequently
the sections were rehydrated. After washing in PBS, antigen
retrieval treatment for the antibodies CSLEX1, anti-VEGF-C
and anti-VEGF-D was done by boiling the sections in 1 mM
EDTA (ethylene diamine tetra acetic acid, pH 8.0) solution
during 10 min. Antigen retrieval for anti-CD31 and D2–40
was done by boiling the sections in a 0.01 M sodium citrate
solution (pH 6.0) during 10 min. After applying the primary
antibodies, the sections were incubated overnight at room
temperature. Detection of the antigen was achieved by
incubating the sections for 30 min with the biotinylated
rabbit-anti-mouse conjugate (Dako, Glostrup, Denmark,
1:200)orwithbiotinylatedswine-anti-rabbitconjugate(Dako,
Glostrup,Denmark,1:400)forVEGF-Candincubationfor30
min with a streptavidin-biotin-peroxidase conjugate (DAKO,
Glostrup, Denmark, 1:100). For the staining with anti-CD31
and D2–40, detection of the antigen was achieved with
Envision (Dako, Glostrup, Denmark). The sections were
developed in 3,3-di-amino-benzidine tetrahydrochloride
(DAB) substrate in a buffered 0.05 M Tris/HCl (pH 7.6)
solution containing 0.002% hydrogen peroxide leading to
brown-staining of the antigen. Counterstaining was done with
Mayer’s Haematoxylin. For microscopic analysis the sections
were dehydrated and mounted in pertex. Tumor cells positive
forsLeX,VEGF-CorVEGF-DandvesselspositiveforCD31
or D2–40 stained brown.
Quantification
Slides were evaluated by using a standard light microscope.
At least two investigators (Doekhie, Morreau, Speetjens or
Dekker)independentlyexaminedeachstaininganddiscordant
cases were re-evaluated to reach consensus. Tissue sections
whichweretoomuchdamagedbythestainingprocedurewere
excluded from further analysis, leading to a variable number
of examined slides (Tables 2 and 3).
Sialyl LeX staining with CSLEX1 showed immunore-
activity of apical cell membranes, cytoplasm of tumor cells
and secretory material in luminal spaces as reported
previously [9]. For the sLeX expression the percentage of
cytoplasmic stained tumor cells and apical membrane
stained tumor cells were separately estimated at 100x
magnification. VEGF-C and VEGF-D expression showed
cytoplasmic localization. In these stainings, the percentage
of cytoplasmic stained tumor cells was estimated, also at
100x magnification.
Microvessel density was assessed in sections stained by
anti-CD31 and D2–40 antibodies, as described previously
[15]. Three fields with the highest vascular density (hot
spots) were identified both within intratumoral stroma and
the invasive front if present, using 50x and 100x magnifi-
cation. Subsequently, the number of vessels was counted
using 200x magnification after applying a 10×10 grid on
the hot spots corresponding to an area of 0.25 mm
2. All
vessels hitting two of the sides of the grid were included in
the count, whereas vessels hitting the other two sides of the
grid were excluded from the count, using the principles of
Gundersen et al. [19]. Microvessels in the submucosa
served as internal controls in assessing the quality of staining
for CD31 and D2–40. Any immunoreactive endothelial
cell or endothelial cell cluster that was clearly separated
from the adjacent microvessels was considered as a single
countable microvessel. The occasionally found immuno-
reactive lymphocytes, macrophages, and plasma cells
were excluded on the basis of the staining pattern and
Table 2 Sialyl Lewis X and vascular endothelial growth factor C and D cytoplasmic staining in primary colorectal tumors (n=99)
a
All patients Cases Controls P
b Univariate analysis
Number Percent Number Percent Number Percent OR 95% CI P value
CSLEX1
Negative 25 25 3 9 22 33 0.012 1
Positive 74 75 29 91 45 67 4.7 (1.3–17.2) 0.019
VEGF-C
Negative 67 68 18 56 49 73 0.093 1
Positive 32 32 14 44 18 27 2.1 (0.9–5.1) 0.096
VEGF-D
Negative 88 89 26 79 62 94 0.039
c 1
Positive 11 11 7 21 4 6 4.2 (1.1–15.5) 0.033
VEGF Vascular endothelial growth factor, OR odds ratio, CI confidence interval
aPrimary tumors from three controls could not be retrieved from the archive and tissue sections which were destroyed after staining were excluded
from analysis leading to a lower number of examined slides
bChi-square test of cases versus controls, unless mentioned otherwise
cFisher’s exact test
144 F.S. Doekhie et al.cell morphology. Regions of necrosis were excluded from
analysis.
Blood and lymphatic vessel invasion was assessed in HE
stained sections and in sections stained with antibodies
directed against CD31 or D2–40. In HE stained sections,
the presence of tumor cells in luminal spaces lined by
endothelial cells in peritumoral stroma was scored as blood
or lymphatic vessel invasion. On immunohistochemically
stained sections, the presence of tumor cells inside a CD31
or D2–40 stained vessel was considered as blood or
lymphatic vessel invasion.
Statistical Analysis
Statistical analysis was carried out using SPSS software,
version 12.0.1 (SPSS Inc, Chicago, IL). For both blood and
lymphatic vessels, statistical analysis was performed using
the maximum number of counted vessels in the hot spots as
was also done in a recent study in which the same
antibodies were used [20]. Numerical data are presented
as mean±standard deviation or as median and range in case
of skewness. The clinicopathologic features of cases and
controls were compared either by a Chi-square test, Student
T-test or Mann–Whitney test. Univariate and multivariate
odds ratio’s (OR), 95% confidence intervals (95% CI) and
p-values (P) were calculated by applying logistic regression
analysis with patient’s clinical outcome as dependent
variable. Parameters with a (overall) p-value less than
0.10 in the univariate analysis were entered into the
multivariate logistic regression model.
Results
Standard Patient and Histopathological Characteristics
No significant difference in sex, T stage, tumor size, tumor
location, tumor differentiation, mucinous tumors, number
of harvested lymph nodes and serum CEA level was seen
between the case and control group. We did see that
patients from the case group were significantly more often
identified with tumors showing an infiltrative growth
pattern in comparison to patients from the control group
(Chi-square test, 41% versus 21%, P=0.031). Patient
characteristics are shown in Table 1 and univariate analysis
of clinicopathological characteristics is shown in Table 4.
Expression of Sialyl Lewis X, VEGF-C and VEGF-D
Membrane and cytoplasmic staining for CSLEX1 were
scored separately. Membrane and cytoplasmic staining
respectively was seen in 91 and 74 of 99 examined
CSLEX1 stained sections. Significantly more cases than
Table 3 Microvessel density and microvessel tumor invasion in primary colorectal tumors
a
All patients Cases Controls P
e Univariate analysis
Number Percent Number Percent Number Percent OR 95% CI P value
BMVD invasive front (n=90)
b, c
Low 76 84 24 75 52 90 0.077
f 1
High 14 16 8 25 6 10 2.9 (0.9–9.3) 0.074
LMVD tumor stroma or invasive front (n=91)
b, d
Low 72 79 22 67 50 86 0.027 1
High 19 21 11 33 8 14 3.1 (1.1–8.8) 0.032
Blood vessel invasion (n=96)
Absent 95 99 32 97 63 100 0.344
f NA
Present 1 1 1 3 0 0
Lymphatic vessel invasion (n=96)
Absent 88 92 28 85 60 95 0.119
f 1
Present 8 8 5 15 3 5 3.6 (0.8–16.0) 0.096
BMVD Blood microvessel density, LMVD lymphatic microvessel density, OR odds ratio, CI confidence interval, NA not assessable
aPrimary tumors from three controls could not be retrieved from the archive and tissue sections which were destroyed after staining were excluded
from analysis leading to a variable number of examined slides; blood microvessels were stained with anti-CD31 antibodies and lymphatic vessels
were stained with D2–40 antibodies
bMaximum number of counted vessels from hot spots; invasive front was not present on all sections
cHigh: greater than 46
dHigh: greater than 20
eChi-square test of cases versus controls, unless mentioned otherwise
fFisher’s exact test
Prognostic factors in colorectal cancer 145controls showed cytoplasmic staining for CSLEX1 (Chi-
square test, 91% versus 67%, P=0.012) (Table 2). No
difference in membrane staining was seen between the case
and control group.
More cases than controls were identified with cytoplasmic
positively stained tumor cells for VEGF-C (Chi-square test,
44% versus 27%, P=0.093) and VEGF-D (Fisher’se x a c t
test, 21% versus 6%, P=0.039) (Table 2). Representative
immunohistochemical stainings for CSLEX1, VEGF-C and
VEGF-D are shown in Fig. 1. Cytoplasmic background
staining was seen in negative controls for the VEGF-C
staining. Tumors negative for VEGF-C showed similar
background staining which could be clearly differentiated
from positive staining for VEGF-C (Fig. 1e,f). The univariate
analysis of these angiogenesis and lymphangiogenesis-
related tumor cell markers is shown in Table 2.
Blood and Lymphatic Microvessel Density
We choose to count blood and lymphatic microvessels in
three hot spots (i.e. fields with the highest vascular density)
located in intratumoral stroma and three hot spots at the
invasive front. Blood microvessels stained by anti-CD31
antibodies were seen in tumor stroma or the invasive front
in all of 96 analyzed primary tumors (100%) and lymphatic
microvessels stained by D2–40 antibodies were seen in
78 of 96 (81%) analyzed primary tumors. As previously
shown [21, 22], we found that anti-CD31 antibodies did not
stain D2–40 positive lymphatic vessels and vice versa (Fig.
2). We counted more blood microvessels (39±12; median
37; range 12 to 80) than lymphatic microvessels (14±9;
median 15; range 0 to 42). Patients with more than 46
blood microvessels in the invasive front (high BMVD)
were more often seen in the case than in the control group
(Fisher’s exact test, 25% versus 10%, P=0.077), but it did
not reach significance (Table 3). Significantly more patients
with more than 20 lymphatic microvessels in tumor stroma
or invasive front (high LMVD) were seen in the case group
than in the control group (Chi-square test, 33% versus 14%,
P=0.027) (Table 3).
Concluding, overall more blood microvessels than
lymphatic microvessels were observed. In the case group,
a higher number of blood and lymphatic microvessels was
seen compared to the control group.
Blood and Lymphatic Vessel Invasion
Blood and lymphatic vessel invasion detected on HE
stained sections will be referred to as morphological vaso-
invasion. In 49 of 108 (45%) primary tumors, morphological
vaso-invasion was found.
Lymphatic vessel invasion was seen in 8 of 96 (8%) D2–
40 stained tumor sections (Fig. 3a,b) and blood vessel
invasion was only seen in one of 96 (1%) sections stained
with antibodies directed against CD31 (Fig. 3c,d). Seven of
the 8 patients with lymphatic vessel invasion detected on
the D2–40 stained sections had been recognized on the HE
stained sections and the one tumor with blood vessel
invasion was also seen on the HE stained section (Fig. 3g).
These results show that morphological vaso-invasion
scored on HE stained sections overestimated the actual
blood and lymphatic vessel invasion as seen after immu-
nohistochemical staining.
Relation between studied variables
We assessed mutual correlation between the different
markers that were investigated. We found that 10 of 11
tumors showing positive staining for VEGF-D were also
positive for VEGF-C (Chi-square test, P<0.001).
Significantly more patients with positively stained tumor
cells for VEGF-C showed a high LMVD compared to
patients negative for VEGF-C (Chi-square test, 11 of 31
versus 8 of 59, P=0.015) indicating an association between
VEGF-C expression and lymphangiogenesis. Sialyl Lewis
Table 4 Univariate analysis of clinicopathological characteristics
Characteristics Univariate analysis
OR 95% CI P value
Sex
Female 1
Male 1.3 (0.6–3.0) 0.497
Age (years) 1.0 (0.97–1.03) 0.910
T stage
T2 and T3 1
T4 3.1 (1.0–9.9) 0.050
Tumor size (cm) (n=104) 0.9 (0.8–1.2) 0.536
Tumor location
Colon (coecum–sigmoid) 1
Rectum (rectosigmoid–rectum) 0.9 (0.3–2.6) 0.858
Differentiation 0.913
a
Good 1
Moderate 1.0 (0.4–2.5) 0.927
Poor 1.3 (0.3–4.9) 0.750
Number of lymph nodes 0.9 (0.9–1.0) 0.132
Mucinous
No 1
Yes 1.4 (0.4–5.2) 0.640
Growth pattern
Expanding or pushing 1
Infiltrating 2.7 (1.1–6.7) 0.034
Preoperative serum CEA level (n=43)
<6 ug/l 1
≥6 ug/l 2.2 (0.5–10.2) 0.303
OR Odds ratio, CI confidence interval, CEA carcinoembryonic antigen
aOverall P-value
146 F.S. Doekhie et al.Fig. 1 CSLEX1, VEGF-C and VEGF-D expression in colorectal
tumors. A tumor negatively stained (a) and positively stained (b) for
CSLEX1; this tumor showed both membrane and cytoplasmic brown
staining. A tumor with negative (c) and positive cytoplasmic brown
staining (d) for VEGF-C; similar faint cytoplasmic brown staining as
shown in negatively stained tumors for VEGF-C was seen in
phosphate buffered saline controles for the VEGF-C staining; this
background staining could be clearly differentiated from positive
cytoplasmic brown staining for VEGF-C. A tumor with negative (e)
and positive cytoplasmic brown staining (f) for VEGF-D; a brown
stromal background staining was seen
Fig. 2 Visualization of
lymphatic and blood vessels in
colorectal tumors. Lymphatic
vessels were stained brown
when using immunohistochem-
istry by the antibodies D2–40
(a). These lymphatic vessels
showed no staining by immu-
nohistochemistry when using
antibodies CD31 (b). Blood
vessels were not recognized by
D2–40 (c) but were brown
stained by CD31 (d)
Prognostic factors in colorectal cancer 147X expression seemed to be related to an infiltrating type of
tumor growth as significantly more of these tumors showed
cytoplasmic positive staining with CSLEX1 (Chi-square
test, 24 of 27 versus 46 of 68, P=0.034) compared to
tumors with an expanding growth pattern. Also significantly
moreinfiltratingtumorsshowedmorphological vaso-invasion
compared to expanding tumors (Chi-square test, 19 of 27
versus 27 of 70, P=0.005). This correlation suggests a role
of infiltrating tumor growth in the overestimation of blood
and lymphatic vessel invasion in the morphological vaso-
invasion score.
Logistic Regression Analysis
All variables with a p- v a l u el o w e rt h a n0 . 1 0i nt h e
univariate analysis (Tables 2, 3 and 4) were entered in a
forward step multivariate analysis. T stage, tumor growth
pattern, CSLEX1-, VEGF-C- or VEGF-D-expression, high
BMVD, high LMVD and lymphatic vessel invasion were
entered in the multivariate analysis. The independent
factors predicting disease recurrence that remained were
sLeX tumor expression by CSLEX1 and a high LMVD
(OR 5.1, 95% CI 1.3–20.0 and OR 3.1, 95% CI 1.0–10.0,
respectively).
Correlation with Site of Metastases
The site of the metastases was registered in our hospital,
which enabled us to assess its correlation with the different
variables tested. Primary tumors with CSLEX1 expression
significantly more often led to disease recurrence in the
liver compared to primary tumors negative for CSLEX1
(Chi-square test, 20 of 74 versus one of 25, P=0.015).
Liver metastases were also significantly more often seen in
the patients with infiltrative tumors than in patients with
expanding tumors (Chi-square test, 11 of 27 versus 11 of
70, P=0.008).
Patients with a high BMVD in the invasive front
developed lung metastases significantly more often than
patients with a low BMVD in the invasive front (Fisher’s
exact test, 4 of 14 versus 4 of 76, P=0.018).
The chance to develop regional, peritoneal or metastases
to the brain, bones or adrenal glands was significantly
higher in patients with high LMVD compared to patients
with low LMVD (Fisher’s exact test, 8 of 19 versus 8 of 72,
P=0.004). This chance also significantly increased with the
T stage (Fisher’s exact, T4 stage: 6 of 14 versus T2 or T3
stage: 12 of 94, P=0.012) and decreased with the number
of harvested lymph nodes (Fisher’s exact test, 0 of 22 in
patients with 12 or more examined lymph nodes versus
18 of 86 in patients with less than 12 lymph nodes, P=
0.021). Moreover, no correlation was seen between a high
LMVD, T4 stage or 12 or more harvested lymph nodes.
When entering these three variables in a multivariate
analysis, a high LMVD remained as an independent
predictor for regional, peritoneal or metastases to distant
sites other than liver and lungs (OR 7.3, 95% CI 2.0–27.4,
P=0.003).
Fig. 3 Tumor cell invasion in
lymphatic and blood vessels in
colorectal tumors. Lymphatic
vessel invasion seen on a
hematoxylin and eosin stained
section (a) and immunohisto-
chemically stained section by
the antibodies D2–40 (b);
lymphatic vessels were brown
stained by D2–40. Blood vessel
invasion seen on a hematoxylin
and eosin stained section (c) and
immunohistochemically stained
section by the antibodies CD31
(d); blood vessels were brown
stained by CD31
148 F.S. Doekhie et al.Discussion
In this study, we show sLeX expression and a high LMVD
of the primary tumor to be independent risk factors for
disease recurrence in curatively resected CRC patients with
tumor-negative lymph nodes. Our results confirm data from
Nakagoe et al. [9] showing that lymph node-negative CRC
patients with sLeX expression detected with CSLEX1 have
a worse prognosis. Moreover, we showed a significant
correlation between sLeX expression and liver metastases
as previously reported by others [23, 24]. We saw a cor-
relation between sLeX expression and infiltrative tumor
growth pattern and showed the latter also to correlate with
disease recurrence [18]. The reproducibility of tumor
growth pattern assessment has been shown to be problematic
[25] which suggests growth pattern to be an unreliable
prognostic marker in contrast with sLeX immunohisto-
chemical detection. Our results suggest that sLeX expression
plays a role in infiltrative tumor growth and in facilitating the
hematogenous spread of tumor cells through blood micro-
vessels via the portal vein to the liver.
The lymphatic system has also been believed to be one
of the most important pathways for tumor cell dissemina-
tion as it is expected that tumor cells can enter lymphatic
microvessels easier than blood microvessels because the
former show a discontinuous or completely absent base-
ment membrane and are devoid of pericytes [26]. Years of
research have resulted in several lymphatic endothelial cell
specific markers [26]. In this study, we used D2–40 which
was reported to be more sensitive in detecting lymphatic
endothelium than Prox1, LYVE-1 and podoplanin [27]. We
found a high LMVD detected with D2–40 to be an
independent risk factor for disease recurrence. Similar find-
ings were seen by Matsumoto et al. [28] who used the anti-
podoplanin antibody to detect lymphatic microvessels in
primary tumors of 106 stage I to IV CRC patients. They
showed a high LMVD and lymphatic vessel invasion to
correlate with a poor outcome but only the former remained
as an independent predictor in the multivariate analysis. Saad
et al. [20] examined BMVD and LMVD in 90 stage I to IV
CRC patients by using anti-CD31 and D2–40 antibodies,
respectively. They observed a significant correlation between
LMVD and liver metastases, but they did not analyze other
types of distant metastases. In our study, a high LMVD
was found not to correlate with liver metastases or lung
metastases but with regional intra-abdominal or intrapelvic
metastases in lymph nodes and other distant metastases such
as peritoneum, bones, brain and adrenal glands. We suggest
that a high LMVD leads to tumor cell dissemination through
lymphatic microvessels into intra-abdominal or pelvic lymph
nodes. The lymphatic system finally returns lymph to the
systemic blood circulation via the thoracic duct leading to
metastases in the bones, brain and other distant sites.
Additionally, a high BMVD correlated with disease
recurrence restricted to the lungs. This may explain the
variability in published studies regarding the prognostic
relevance of BMVD as it probably depends on the number
of patients in those particular studies who suffered from
disease recurrence in the lungs. Accordingly, a recent meta-
analysis showed a high BMVD, detected by using anti-
bodies directed against CD31 or CD34, to significantly
predict poor clinical outcome [29].
We assessed tumor invasion in blood and lymphatic
vessels on HE stained sections and referred to this as
morphological vaso-invasion. By comparing morphological
vaso-invasion and blood and lymphatic vessel invasion
scored on immunohistochemically stained sections, we
found the former to be overestimated as reported previously
by others [30]. Analysis suggested that scoring of morpho-
logical vaso-invasion does not distinguish between blood or
lymphatic vessel invasion and an infiltrative tumor growth
pattern. Previous studies have shown that artifactual tissue
retraction around tumor islands complicate and overestimate
truelymphovascularinvasion[16, 17]. Immunohistochemical
staining of blood and lymphatic vessels with specific
antibodies resolves this problem and enables objective
estimation of tumor invasion in vessels.
To our knowledge, we are the first to identify a multiple
set of tumor markers each correlating with a different
preferential site of metastasis in CRC. Our results support
two types of mechanisms involved in metastasis. First,
there is the mechanical way of tumor cell dissemination
through blood and lymphatic microvessels, resulting in
tumor cell arrest in the narrow capillary network in
different organs including lymph nodes. There they may
proliferate and develop clinically evident metastases.
Hematogenous and lymphatic metastasis is expected to
increase with the number of blood and lymphatic micro-
vessels. This may explain the correlation between a high
BMVD and lung metastases and the correlation between
a high LMVD and regional intra-abdominal or intra-
pelvic metastases in lymph nodes with eventually distant
metastases.
In addition to this mechanical entrapment of tumor cells,
also biological processes determine outgrow of metastases
as explained by the “seed and soil” theory [31, 32]. This
theory suggests that a subpopulation of tumor cells with
metastatic potential, recently identified as colon-cancer-
initiating cells [33], disseminate through the whole body.
These cells proliferate and differentiate to form clinically
evident metastases at preferential sites depending on local
molecular interaction among which availability of local
growth factors. In our study, the correlation between sLeX
expression and liver metastases may be explained by this
pathway. The interaction of the antigen sLeX on tumor cells
and E-selectin on endothelial cells was shown to mediate
Prognostic factors in colorectal cancer 149adhesion of tumor cells to endothelial cells [8] possibly
facilitating tumor cell invasion in blood microvessels,
extravasation and migration into tissue. Additionally,
colorectal tumor cells showing sLeX expression might
prefer the liver to grow out to form clinically evident
metastases due to interaction with local E-selectin [34].
It is important to realize that this study regards a small
patient group but even in these small patient numbers we
showed significant findings consistent with current thoughts
in terms of hematogenous and lymphatic metastasis. Further-
more, only 20% of our patient group had undergone an
adequate lymph node harvest of at least 12 lymph nodes as
recommended by the American Joint Committee on Cancer
Staging[35], which is a limitation of our study. Nevertheless,
similar numbers were reported by Johnson et al. [36]a n d
Baxter et al. [37] who showed adequate lymph node
evaluation in 22% of 569 CRC specimens respectively
37% of 116995 CRC patients. They reported the effect of
different pathology assistants, older age and rectal cancer to
affect the number of lymph nodes retrieved [37, 38].
In summary, our study shows that high-risk lymph node-
negative CRC patients can be identified by assessing the
primary tumor for sLeX expression with CSLEX1 and
LMVD. Our results have to be validated in prospective
studies which should also evaluate whether these high-risk
CRC patients may benefit from adjuvant systemic therapy.
Moreover, our results are consistent with the notion that
both a lymphatic and hematogenous route plays a role in
CRC.
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